1. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: relevance to chemotherapy

   • Osama M. Ashour
   • Omar N. Al Safarjalani
   • Mahmoud H. el Kouni

   ORIGINAL ARTICLE Pages: 351 - 361

2. P53 status plays no role in radiosensitizing effects of SN-38, a camptothecin derivative

   • Xuejun Xie
   • Keisuke Sasai
   • Masahiro Hiraoka

   ORIGINAL ARTICLE Pages: 362 - 368

3. The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization

   • Mei Chen
   • Amanda M. Hough
   • Theodore S. Lawrence

   ORIGINAL ARTICLE Pages: 369 - 374

4. In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy

   • Patrice Nony
   • Jean-Paul Guastalla
   • Marc Janier

   ORIGINAL ARTICLE Pages: 375 - 380

5. Increase in tumor GADD153 mRNA level following treatment correlates with response to paclitaxel

   • Maida M. de las Alas
   • Randolph D. Christen
   • Gerrit Los

   ORIGINAL ARTICLE Pages: 381 - 388

6. Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis

   • Chung-Tsen Hsueh
   • Chang-Fang Chiu
   • Gary K. Schwartz

   ORIGINAL ARTICLE Pages: 389 - 396

7. Evaluation of antidotes for extravasation injury produced by 6-hydroxymethylacylfulvene (MGI 114), a novel cytotoxic antitumor agent, in an intradermal toxicity model in rats

   • Richard F. Marshall
   • Larry E. Arthaud
   • John R. MacDonald

   ORIGINAL ARTICLE Pages: 397 - 401

8. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients

   • Juha Ellmén
   • Dudley Werner
   • W. R. Bezwoda

   ORIGINAL ARTICLE Pages: 402 - 408

9. Identification and proposed mechanism of action of thymidine kinase inhibition associated with cellular exposure to camptothecin analogs

   • Donna M. Voeller
   • Jean L. Grem
   • Carmen J. Allegra

   ORIGINAL ARTICLE Pages: 409 - 416

10. Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs

    • Graeme J. Finlay
    • Bruce C. Baguley

    ORIGINAL ARTICLE Pages: 417 - 422

11. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks

    • John D. Roberts
    • Stephen Shibata
    • Neil J. Clendeninn

    ORIGINAL ARTICLE Pages: 423 - 427

12. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma)

    • C. M. F. Kruijtzer
    • J. H. Beijnen
    • J. H. M. Schellens

    CLINICAL TRIAL REPORT Pages: 428 - 431

13. Nasal absorption of ondansetron in rats: an alternative route of drug delivery

    • Anwar A. Hussain
    • Adnan Dakkuri
    • Soichi Itoh

    SHORT COMMUNICATION Pages: 432 - 434

14. Acknowledgement to reviewers

    Pages: 435 - 436